Phaseline

Companies › Rein Therapeutics

Rein Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LTI-03
Caveolin-1-scaffolding-protein-derived peptide
CAV1Phase 2Idiopathic Pulmonary Fibrosis (IPF)Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06968845LTI-03Phase 2Idiopathic Pulmonary Fibrosis (IPF)RespiratorySep 2027

From the company's SEC filings

Cash and short-term investments of $44m on 2026-06-30; operating cash outflow about $24m a year; runway about 21 months at that burn, to Apr 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CAV1 (1)

Companies with the same targets

–

Companies built like this

aTyr Pharma Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.